Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Sep 30, 2026

Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC

Aug 28, 2026

Cantargia to Participate in Upcoming Investor Conferences

Aug 19, 2026

(R) Cantargia publishes Half-Year Report 2026

Aug 4, 2026

Cantargia to host Q2 2026 Interim Results Conference Call

Jul 31, 2026

(R) Cantargia Announces Changes in Number of Shares and Votes

Jun 26, 2026

Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC

Jun 23, 2026

(R) Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital

Jun 11, 2026

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

Jun 10, 2026

Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study

Jun 5, 2026

(R) Cantargia publishes Information Document regarding Rights Issue of Shares

Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye